A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...